Skip to main content
Clinical Trials/ISRCTN10567920
ISRCTN10567920
Active, Not Recruiting
N/A

A pragmatic, cluster randomized trial evaluating the impact of an enhanced adherence package (dual bronchodilator + add-on + app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year

Observational and Pragmatic Research International Ltd0 sites1,312 target enrollmentJuly 25, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic obstructive pulmonary disease (COPD)
Sponsor
Observational and Pragmatic Research International Ltd
Enrollment
1312
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34079422/ (added 04/06/2021)

Registry
who.int
Start Date
July 25, 2019
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Observational and Pragmatic Research International Ltd

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 06/09/2023:
  • For a practice to be eligible for participation, the following criteria should be met:
  • 1\. General practice in the United Kingdom (England, Scotland, Wales, Northern Ireland) participating in Optimum Patient Care services that support chronic disease review and provide high\-quality respiratory data
  • 2\. Willing to use advanced technology as part of clinical practice
  • 3\. At least 8 patients suitable for adherence technology
  • 4\. Actively prescribing Ultibro® Breezehaler® as a routine clinical care option; (i.e. inhaler compatible with the add\-on technology)
  • Patients suitable for adherence technology support:
  • 1\. Aged \=40 years
  • 2\. Ever\-smoker
  • 3\. On the COPD register of participating practices

Exclusion Criteria

  • Current exclusion criteria as of 06/09/2023:
  • Practice exclusion criteria:
  • 1\. General practice not prescribing Ultibro® as part of routine clinical care to patients with COPD
  • 2\. General practices hosting or affected by research, or other aspects of care, which might significantly influence the practice\-wide implementation
  • Patient exclusion criteria:
  • 1\. Patients with a consent refusal code indicating opt\-out of data used for research
  • 2\. Patients not deemed clinically appropriate for the therapy which is technology\-compatible
  • 3\. Patients on triple therapy (ICS/LABA/LAMA)
  • 4\. Read code for asthma (excluding ‘asthma resolved’ read codes)
  • 5\. Blood eosinophil count \>300 cells/µl if blood count available in the last 12 months

Outcomes

Primary Outcomes

Not specified

Similar Trials